Int J Angiol 2020; 29(02): 088-097
DOI: 10.1055/s-0040-1708477
Invited Articles
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians

Anwar Santoso
1   Department of Cardiology—Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
2   National Cardiovascular Centre, Harapan Kita Hospital, Jakarta, Indonesia
,
1   Department of Cardiology—Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
2   National Cardiovascular Centre, Harapan Kita Hospital, Jakarta, Indonesia
› Author Affiliations
Further Information

Publication History

Publication Date:
06 May 2020 (online)

Abstract

Atrial fibrillation (AF), the most prevalent arrhythmic disease, tends to foster thrombus formation due to hemodynamic disturbances, leading to severe disabling and even fatal thromboembolic diseases. Meanwhile, patients with AF may also present with acute coronary syndrome (ACS) and coronary artery disease (CAD) requiring stenting, which creates a clinical dilemma considering that majority of such patients will likely receive oral anticoagulants (OACs) for stroke prevention and require additional double antiplatelet treatment (DAPT) to reduce recurrent cardiac events and in-stent thrombosis. In such cases, the gentle balance between bleeding risk and atherothromboembolic events needs to be carefully considered. Studies have shown that congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, and previous stroke or transient ischemic attack (TIA; doubled)–vascular disease, age 65 to 74 years, sex category (female; CHA2DS2-VASc) scores outperform other scoring systems in Asian populations and that the hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly (>65 years), drugs/alcohol concomitantly (1 point each; HAS-BLED) score, a simple clinical score that predicts bleeding risk in patients with AF, particularly among Asians, performs better than other bleeding scores. A high HAS-BLED score should not be used to rule out OAC treatment but should instead prompt clinicians to address correctable risk factors. Therefore, the current review attempted to analyze available data from patients with nonvalvular AF who underwent stenting for ACS or CAD and elaborate on the direct-acting oral anticoagulant (DOAC) and antiplatelet management among such patients. For majority of the patients, “triple therapy” comprising OAC, aspirin, and clopidogrel should be considered for 1 to 6 months following ACS. However, the optimal duration for “triple therapy” would depend on the patient's ischemic and bleeding risks, with DOACs being obviously safer than vitamin-K antagonists.

 
  • References

  • 1 Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol 2008; 52 (10) 865-868
  • 2 Yan L, Fan Z. Progress in the new drugs for treatment of atrial fibrillation. Zhongguo Lin Chuang Yao Li Xue Za Zhi 2011; 1: 64-67
  • 3 Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014; 11 (11) 639-654
  • 4 Lip GYH, Potpara T, Boriani G, Blomström-Lundqvist C. A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. J Intern Med 2016; 279 (05) 467-476
  • 5 Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. Thromb Haemost 2018; 118 (12) 2014-2017
  • 6 Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017; 117 (07) 1230-1239
  • 7 Leon MB, Baim DS, Popma JJ. , et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339 (23) 1665-1671
  • 8 Connolly SJ, Pogue J, Hart RG. , et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360 (20) 2066-2078
  • 9 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
  • 10 Granger CB, Alexander JH, McMurray JJV. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
  • 11 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
  • 12 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
  • 13 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
  • 14 Lane DA, Dagres N, Dan GA. , et al. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Europace 2019; 21 (07) 1116-1125
  • 15 Fukamachi D, Hirayama A, Miyauchi K. , et al. Antithrombotic therapy trends in non-valvular atrial fibrillation patients undergoing percutaneous coronary stent implantation: results from a survey among fellows at the Japanese College of Cardiology. J Cardiol 2018; 72 (02) 113-119
  • 16 January CT, Wann LS, Calkins H. , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74 (01) 104-132
  • 17 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation. JAMA 2001; 285 (22) 2864-2870
  • 18 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
  • 19 Chao TF, Lin YJ, Tsao HM. , et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 2011; 58 (23) 2380-2385
  • 20 Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5 (02) 319-326
  • 21 Fauchier L, Lecoq C, Ancedy Y. , et al. Evaluation of 5 prognostic scores for prediction of stroke, thromboembolic and coronary events, all-cause mortality, and major adverse cardiac events in patients with atrial fibrillation and coronary stenting. Am J Cardiol 2016; 118 (05) 700-707
  • 22 Capodanno D, Rossini R, Musumeci G. , et al. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol 2015; 199: 319-325
  • 23 Kirchhof P, Benussi S, Kotecha D. , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18 (11) 1609-1678
  • 24 Singer DE, Chang Y, Borowsky LH. , et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2 (03) e000250
  • 25 Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013; 346: f2573
  • 26 Hijazi Z, Lindbäck J, Alexander JH. , et al; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37 (20) 1582-1590
  • 27 Lip GYH, Collet JP, Haude M. , et al; ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2019; 21 (02) 192-193
  • 28 Chao TF, Liu CJ, Tuan TC. , et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians?. Heart Rhythm 2016; 13 (01) 46-53
  • 29 Chao TF, Liu CJ, Wang KL. , et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 2014; 64 (16) 1658-1665
  • 30 Chiang CE, Okumura K, Zhang S. , et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm 2017; 33 (04) 345-367
  • 31 Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 2009; 101 (05) 938-942
  • 32 Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113 (03) 485-490
  • 33 Chiang CE, Wu TJ, Ueng KC. , et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc 2016; 115 (11) 893-952
  • 34 Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111 (05) 789-797
  • 35 Chao TF, Wang KL, Liu CJ. , et al. Age threshold for increased stroke risk Among patients with atrial fibrillation: A nationwide cohort study From Taiwan. J Am Coll Cardiol 2015; 66 (12) 1339-1347
  • 36 Chan PH, Lau CP, Tse HF, Chiang CE, Siu CW. CHA2DS2-VASc recalibration With an additional age category (50–64 years) enhances stroke risk stratification in Chinese patients With atrial fibrillation. Can J Cardiol 2016; 32 (12) 1381-1387
  • 37 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
  • 38 Fang MC, Go AS, Chang Y. , et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58 (04) 395-401
  • 39 O'Brien EC, Simon DN, Thomas LE. , et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36 (46) 3258-3264
  • 40 Hijazi Z, Oldgren J, Lindbäck J. , et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
  • 41 Roldán V, Marín F, Manzano-Fernández S. , et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2013; 62 (23) 2199-2204
  • 42 Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost 2013; 110 (05) 1074-1079
  • 43 Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016; 14 (09) 1711-1714
  • 44 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33 (12) 1500-1510
  • 45 Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60 (09) 861-867
  • 46 Proietti M, Senoo K, Lane DA, Lip GY. Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores. Sci Rep 2016; 6: 24376
  • 47 Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med 2016; 129 (06) 600-607
  • 48 Naganuma M, Shiga T, Sato K. , et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. Thromb Res 2012; 130 (01) 21-26
  • 49 Chang TY, Lip GYH, Chen SA, Chao TF. Importance of risk reassessment in patients with atrial fibrillation in guidelines: assessing risk as a dynamic process. Can J Cardiol 2019; 35 (05) 611-618
  • 50 Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for occluded coronary arteries. J Am Coll Cardiol 1997; 30 (02) 406-413
  • 51 Rathore SS, Berger AK, Weinfurt KP. , et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 2000; 101 (09) 969-974
  • 52 Goldberg RJ, Seeley D, Becker RC. , et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119 (05) 996-1001
  • 53 Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H. ; SPRINT Study Group. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J 1992; 13 (01) 45-50
  • 54 Dewilde WJM, Oirbans T, Verheugt FW. , et al; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107-1115
  • 55 You JJ, Singer DE, Howard PA. , et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e531S-e575S
  • 56 Valgimigli M, Bueno H, Byrne RA. , et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
  • 57 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
  • 58 Roffi M, Patrono C, Collet JP. , et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
  • 59 Valgimigli M, Gagnor A, Calabró P. , et al; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015; 385 (9986): 2465-2476
  • 60 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20 (08) 1231-1242
  • 61 Sarafoff N, Martischnig A, Wealer J. , et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61 (20) 2060-2066
  • 62 Kowalewski M, Suwalski P, Raffa GM. , et al. Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. Int J Cardiol 2016; 223: 186-194
  • 63 Dewilde WJ, Janssen PW, Kelder JC. , et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention 2015; 11 (04) 381-390
  • 64 Kang SH, Chae IH, Park JJ. , et al. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from e network meta-analysis of 147 trials. JACC Cardiovasc Interv 2016; 9 (12) 1203-1212
  • 65 Gorenek B, Blomström Lundqvist C, Brugada Terradellas J. , et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014; 16 (11) 1655-1673
  • 66 Zeymer U, Annemans L, Danchin N. , et al. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. Eur Heart J Acute Cardiovasc Care 2019; 8 (02) 121-129
  • 67 Proietti M, Airaksinen KEJ, Rubboli A. , et al; AFCAS Study Group. Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. Am Heart J 2017; 190: 86-93
  • 68 Faza NN, Mentias A, Parashar A. , et al. Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. Catheter Cardiovasc Interv 2017; 89 (02) E64-E74
  • 69 Verlinden NJ, Coons JC, Iasella CJ, Kane-Gill SL. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticaglerol versus clopidogrel. J Cardiovasc Pharmacol Ther 2017; 22 (06) 546-551
  • 70 Choi HI, Ahn JM, Kang SH. , et al. Prevalence, management, and long-term (6 year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents. JACC Cardiovasc Interv 2017; 10 (11) 1075-1085
  • 71 Fauchier L, Ruiz-Nodar JM, Valdés M, Angoulvant D, Lip GYH, Marín F. Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low-moderate risk of stroke?. Eur J Intern Med 2016; 35: e9-e10
  • 72 Rubboli A, Saia F, Sciahbasi A. , et al; WARfarin and Coronary STENTing (WAR-STENT) Study group. Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry. Cardiovasc Revasc Med 2017; 18 (06) 425-430
  • 73 Sra S, Tan MK, Mehta SR. , et al; Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. Am Heart J 2016; 180: 82-89
  • 74 Sambola A, Mutuberría M, García Del Blanco B. , et al. Impact of triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS One 2016; 11 (01) e0147245
  • 75 Lopes RD, Rao M, Simon DN. , et al. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Am J Med 2016; 129 (06) 592-599 .e1
  • 76 Koskinas KC, Räber L, Zanchin T. , et al. Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2016; 9 (14) 1473-1483
  • 77 Sambola A, Mutuberría M, García Del Blanco B. , et al. Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification. Circ J 2016; 80 (02) 354-362
  • 78 Hess CN, Peterson ED, Peng SA. , et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol 2015; 66 (06) 616-627
  • 79 Fosbol EL, Wang TY, Li S. , et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J 2013; 166 (05) 864-870
  • 80 Gibson CM, Mehran R, Bode C. , et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
  • 81 Fiedler KA, Maeng M, Mehilli J. , et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015; 65 (16) 1619-1629
  • 82 López-López JA, Sterne JAC, Thom HHZ. , et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
  • 83 Badjatiya A, Rao SV. Adavances in antiplatelet and anticoagulant therapies for NSTE-ACS. Curr Cardiol Rep 2019; 21 (01) 3
  • 84 Cannon CP, Bhatt DL, Oldgren J. , et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377 (16) 1513-1524
  • 85 Sindet-Pedersen C, Lamberts M, Staerk L. , et al. Combining oral anticoagulants With platelet inhibitors in patients with atrial fibrillation and coronary disease. J Am Coll Cardiol 2018; 72 (15) 1790-1800
  • 86 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
  • 87 Hori M, Connolly SJ, Zhu J. , et al; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44 (07) 1891-1896
  • 88 Wong KS, Hu DY, Oomman A. , et al; Executive Steering Committee and the ROCKET AF Study Investigators. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014; 45 (06) 1739-1747
  • 89 Yamashita T, Koretsune Y, Yang Y. , et al. Edoxaban vs warfarin in East Asian patients with atrial fibrillation -an ENGAGE AF-TIMI 48 subanalysis. Circ J 2016; 80 (04) 860-869
  • 90 Goto S, Zhu J, Liu L. , et al; ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J 2014; 168 (03) 303-309
  • 91 Wang KL, Lip GY, Lin SJ, Chiang CE. Non-Vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 2015; 46 (09) 2555-2561
  • 92 Wang KL, Giugliano RP, Goto S. , et al. Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. Heart Rhythm 2016; 13 (12) 2340-2347